Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Rated "Hold" by Sell-Side Brokerages

Key Points

• Keros Therapeutics has a consensus “Hold” rating among nine analysts, split between one sell, four hold and four buy recommendations. The average 12-month price target is $20.50, though several firms recently lowered their targets.
• KROS shares opened at $11.28 and have traded between $9.69 and $22.55 over the past year. The company reported a quarterly loss of $1.45 per share, missing the $1.34 analyst consensus, and analysts expect a full-year loss of $5.27 per share.
• The board authorized a $5 million share-repurchase program, allowing the company to buy back up to 2.3% of outstanding shares. Institutional investors own 71.56% of the stock, while insiders have sold shares in recent months.

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been given a consensus rating of "Hold" by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $20.50.

KROS has been the subject of several research reports. Wells Fargo & Company lowered their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. Leerink Partners cut their price target on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 4th. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 27th. Finally, Wall Street Zen cut Keros Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday.

Keros Therapeutics Trading Down 0.6%

NASDAQ KROS opened at $11.28 on Friday. The firm has a market cap of $223.68 million, a price-to-earnings ratio of -3.05 and a beta of 1.12. The company has a 50 day moving average of $11.23 and a 200-day moving average of $11.05. Keros Therapeutics has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. On average, analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its board has authorized a stock repurchase program on Wednesday, September 9th that permits the company to buy back $5.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 2.3% of its stock through open market purchases. Share buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

Insider Transactions at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares of the company's stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock valued at $54,985 over the last ninety days. 12.60% of the stock is currently owned by insiders.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock valued at $33,000 after purchasing an additional 1,166 shares during the last quarter. Quantinno Capital Management LP increased its stake in shares of Keros Therapeutics by 12.5% during the first quarter. Quantinno Capital Management LP now owns 23,759 shares of the company's stock worth $262,000 after purchasing an additional 2,639 shares during the period. Legal & General Group Plc bought a new position in shares of Keros Therapeutics during the second quarter worth approximately $90,000. PDT Partners LLC bought a new position in shares of Keros Therapeutics during the second quarter worth approximately $122,000. Finally, Lazard Asset Management LLC acquired a new stake in Keros Therapeutics during the 1st quarter worth approximately $129,000. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros' investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.